Spyros Papapetropoulos, MD, PhD, is an experienced biopharmaceutical executive and board-certified physician/scientist with a 27-year career in medicine and the biopharmaceutical industry. He currently holds the positions of President, CEO, and Executive Board Member at Neuphoria Therapeutics Inc (NASDAQ: NEUP, f/k/a Bionomics Ltd. NASDAQ: BNOX), founder and Chairman of Phragma Therapeutics Inc and its Greek subsidiary Thera Phragma IKE, Chairman of Lipocine Inc (NASDAQ: LPCN), and founder and President of Encephalos Life Sciences LLC (a privately held consulting firm).
Throughout his career, Dr. Papapetropoulos has led a wide range of biopharmaceutical programs, including small molecules, biologics, gene therapies, digital monitoring platforms, and AI-based discovery platforms. These efforts have resulted in numerous scientific and medical breakthroughs and the commercialization of four novel medications globally. He has also played a key role in multiple successful capital raises, strategic partnerships, and M&A deals, generating billions of dollars in value.
Dr. Papapetropoulos is a serial entrepreneur known for his ability to build and transform companies by bridging the gap between medicine, scientific innovation, and the biopharmaceutical business. He is renowned for creating high-performing teams that prioritize data, science, and culture and for his dedication to patient care and teamwork.
Dr. Papapetropoulos earned his medical and neuroscience degrees from the University of Patras in Greece and completed a clinical fellowship in Movement Disorders/Neurodegenerative diseases at the National Hospital of Neurology and Neurosurgery in London, UK. He has held faculty positions at the University of Miami School of Medicine and served as a Consultant with the Massachusetts General Hospital, Department of Neurology. In addition, he has authored over 170 peer-reviewed publications with approximately 11,000 citations, as well as several patents and book chapters, and has presented and chaired meetings since 1997.
